Complex regulatory network of programmed death-ligand 1 in cancer: Cancer immunomodulation from molecular mechanisms to clinical applications
Summary: Immune checkpoint therapy targeting PD-L1/PD-1 represents a key cancer treatment strategy. PD-L1 binds PD-1 on T cells, suppressing activation and enabling tumor immune escape. Although the blockade of the PD-L1/PD-1 pathway has demonstrated significant anti-tumor effects, the overall respo...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004225008764 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Summary: Immune checkpoint therapy targeting PD-L1/PD-1 represents a key cancer treatment strategy. PD-L1 binds PD-1 on T cells, suppressing activation and enabling tumor immune escape. Although the blockade of the PD-L1/PD-1 pathway has demonstrated significant anti-tumor effects, the overall response rate remains suboptimal in solid tumors. Therefore, understanding the molecular mechanisms underlying PD-L1 deregulation is essential for enhancing the efficacy of PD-L1/PD-1 blockade therapies. As our comprehension of the regulatory mechanisms governing the PD-L1/PD-1 pathway continues to evolve, ongoing exploration of new immunotherapy targets remains critical. This article provides a comprehensive review of recent research concerning the regulation of PD-L1 expression. It encompasses aspects such as its structural characteristics, genomic alterations and rearrangements, epigenetic modifications, inflammatory signaling pathways, oncogenic signaling pathways, microRNA regulation, and post-translational modifications. Additionally, this article illustrates notable advancements and limitations regarding the application of PD-L1 as an immunotherapeutic target in current clinical settings. |
|---|---|
| ISSN: | 2589-0042 |